Gail Tomlinson, MD, PhD

Clinical Associate Professor
Internal Medicine

Contact Information

UT Southwestern Medical Center
5323 Harry Hines Boulevard
Dallas, Texas 75390

gail.tomlinson@utsouthwestern.edu

Biography

Gail E. Tomlinson, MD, PhD

My research and clinical interests are in the area of genetic predisposition to cancer. Ongoing clinical interests include pediatric solid tumors, late effects of cancer treatment, cancer risk assessment, and cancer genetic testing and counseling in high-risk families. I direct the Clinical Cancer Genetics program within the Simmons Cancer Center, which is staffed by three genetic counselors. In this program we see approximately 800 families per year at high risk of the more common tumor types, primarily breast, ovarian and colon cancer.

We have recently initiated a high-risk registry and clinical research program for Von Hippel Lindau Disease. We are also developing cancer genetic counseling programs for pediatric tumors including retinoblastoma and infant brain tumors. These activities take place in the Seay Biomedical Building on the UTSW North Campus and in addition at Moncrief Cancer Resources in Fort Worth and at Children’s Medical Center of Dallas.

My laboratory interests are in 1) genetic factors influencing childhood cancer risk 2) the genetic predisposition to breast cancer, including families with BRCA1, BRCA2, as well as other genes. In the area of pediatric cancers, I have focused in the laboratory primarily on hepatoblastoma and rhabdoid tumors. We recently reported on two genetic polymorphisms which influence the risk of hepatoblastoma the myeloperoxidase gene, variation of which influences relative risk and the cyclin D1 gene, variation of which influences the age of onset. We have also recently characterized translocations involving chromosome 1q12 breakpoints in hepatoblastoma and have identified a novel developmental pathway involved in this tumor type.

In the area of rhabdoid tumor, we recently genetically characterized infants with double primary tumors of the kidney and brain. We also recently completed a genome-wide search for other areas of loss of heterozygosity in rhabdoid tumors of the kidney, many of which were known to have germline hSNF5/INI1 mutations. We observed few overall genomic changes in rhabdoid tumors suggesting that these tumors may not require additional genetic events.

In the area of breast cancer, in collaboration with Dr. Adi Gazdar, my group has worked to develop and characterize two tumor cell lines deficient in BRCA1. The first cell line HCC1937 is derived from a BRCA1-5382insC mutation carrier. This cell line has been used by many laboratories to characterize the function of BRCA1. The second cell line, HCC3153 derives from a carrier of the African American founder mutation BRCA1-943ins10. We are currently looking at the role of genetic modifiers in refinement of breast cancer risk in BRCA1 and BRCA2 families.

Mentoring young investigators interested in translational cancer research is a priority of mine. My lab and research program have been a home for numerous postdoctoral research fellows as well as students including medical students, undergraduate interns and high school seniors. Many of these students have gone on to pursue careers in biomedical research.

 

Education

Graduate SchoolGeorge Washington University (1984)
Graduate SchoolDuke University (1982)

Research Interests

BRCA1 and BRCA2 related familial breast cancer
Cancer genetic predisposition, risk assessment and counseling
Molecular and cytogenetics of genetics of childhood liver and renal tumors
Population specific approaches to cancer risk assessment and counseling

Publications

Featured
Cyclin D1 polymorphism and age of onset of hepatoblastoma

Pakakasama S, Chen T, Frawley W, Lee R, Muller C, Pollock BH, Tomlinson GE , Oncogene , 2004; (23):4789-92

Featured
Variation in the myeloperoxidase gene and risk of hepatoblastoma

Pakakasama S, Chen T, Frawley W, Muller C, Douglass EC , International J. Cancer , 2003; (106):205-7

Featured
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

Euhus DM, Smith KC, Robinson L, Stucky FA, Olopade OI, Cummings S, Garger JE, Chittendon A, Mills GB, Reiger P, Esserman L, Crawford B, Hughes KS, Roche C, Ganz P, Sheldon J, Fabian CJ, Klemp J, Tomlinson G , J. Natl Cancer Institute , 2002; (94):1583-4

Featured
Characterization of a breast cancer cell line derived from a germ-line BRCA1 carrier

Tomlinson GE, Chen TL, Stastny VA, Virmani A, Spillman MA, Tonk VJ, Blum JL, Schneider NJ, Wistuba I, Minna JD, Gazdar AF , Cancer Research , 1998; (58):1605-1608

Featured
Mutation of the hSNF5/INI1 gene in renal rhabdoid tumors with second primary brain tumors

Savla J, Chen T, Schneider NR, Timmons C, Delattre O, Tomlinson G , J. Natl Cancer Institute , ; (92):648-650

Rhabdoid tumor of the kidney in the National Wilms Tumor Study: Age at diagnosis as a prognostic factor

Tomlinson GE, Breslow NE, Dome J, Gurthrie KA, Norkool P, Li S, Thomas PRM, Perlman E, Beckwith JBB, D’Angio GJ, Green DM , J. Clinical Oncology , 2005; (23):7641-5

Cytogenetic analysis of a large series of hepatoblastomas; numerical aberrations with recurring translocations involving 1q12-21

Tomlinson GE, Douglass IC, Pollock BH, Finegold MJ, Schneider NR , Genes, Chromosomes and Cancer , 2005; (44):177-84

MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia

Swinney RM, Hsu SC, Hirschman BA, Chen TTC, Tomlinson GE , Leukemia , 2005; (19):1996-8

The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds

Hirschman BA, Pollock BH, Tomlinson GE , J. Pediatrics , 2005; (147):263-6

Custodianship of genetic information: clinical challenges and professional responsibility

Patterson A, Robinson L, Naftalis E, Haley B, Tomlinson GE , J. Clinical Oncology , 2005; (23):2100-2104

Professional Associations/Affiliations

American Pediatric Society

American Society of Clinical Oncology

Children’s Oncology Group